Opens in new windowAn unsteady geopolitical situation in eastern Europe, worldwide inflation and the politicization of drug pricing in the US all made their mark on 2023.
Making predictions about the biopharma world is always a tricky endeavor but looking ahead into 2024 reveals an uptick in deal-making and perhaps the return of larger scale M&A, as big pharma feels the pressure to fill pipeline gaps at a faster rate.
2024 will perhaps be a transition year as biopharma and medtech companies get through the worst of the market turmoil.
Obesity and CNS diseases are creating fresh growth areas for big pharma. And oncology has bounced back after being overshadowed in the R&D setting by COVID-19. Technological developments hold a lot of promise, but also bring a lot of confusion about best uses. The speed of development for artificial intelligence tools is outpacing the health care sector.
For medtechs, as well as an unstable financial market, environmental demands are adding pressure. Meanwhile, health care systems are grappling with rapid change in the structure of care delivery and how to adjust payment models to facilitate the ongoing move to care delivered in the ambulatory setting and at home.
Outlook 2024 includes exclusive interviews, data, features and industry league tables for Scrip 100, Scrip Asia 100, Medtech 100 and Generics Bulletin’s Top 50.
Lucie Ellis-Tait
Executive Editor, In Vivo
